BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23127971)

  • 41. Omental Biopsy for Surgical Staging of Uterine Serous Carcinoma.
    Luz R; MacDonald N; Mould T
    Int J Gynecol Cancer; 2016 Oct; 26(8):1448-54. PubMed ID: 27465896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy].
    Xue DB; Ding LJ; Xia AL; Chen D; Xia HP; Teng XD; Xu ST; Zhang SJ; Ren XC
    Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):671-4. PubMed ID: 21176532
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
    Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
    Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.
    Solmaz U; Ekin A; Mat E; Gezer C; Dogan A; Biler A; Peker N; Hasdemir PS; Sanci M
    Tumori; 2016 Dec; 102(6):593-599. PubMed ID: 27514313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.
    Bristow RE; Asrari F; Trimble EL; Montz FJ
    Gynecol Oncol; 2001 May; 81(2):279-86. PubMed ID: 11330963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
    Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
    Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
    Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
    Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
    Seagle BL; Dayno M; Strohl AE; Graves S; Nieves-Neira W; Shahabi S
    Gynecol Oncol; 2016 Dec; 143(3):472-478. PubMed ID: 27760707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
    Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
    Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
    Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.
    Hamilton CA; Cheung MK; Osann K; Balzer B; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
    Gynecol Oncol; 2006 Nov; 103(2):679-83. PubMed ID: 16793126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.
    Ahmed Q; Hussein Y; Hayek K; Bandyopadhyay S; Semaan A; Abdul-Karim F; Al-Wahab Z; Munkarah AR; Elshaikh MA; Alosh B; Nucci MR; Van de Vijver KK; Morris RT; Oliva E; Ali-Fehmi R
    Gynecol Oncol; 2014 Feb; 132(2):372-6. PubMed ID: 24262874
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of omentectomy during the surgical staging of uterine serous carcinoma.
    Gehrig PA; Van Le L; Fowler WC
    Int J Gynecol Cancer; 2003; 13(2):212-5. PubMed ID: 12657126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?
    Winer I; Ahmed QF; Mert I; Bandyopadhyay S; Cote M; Munkarah AR; Hussein Y; Al-Wahab Z; Elshaikh MA; Alosh B; Schultz DS; Mahdi H; Nucci MR; Van de Vijver KK; Morris RT; Oliva E; Ali-Fehmi R
    Int J Gynecol Pathol; 2015 Jan; 34(1):47-56. PubMed ID: 25473753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of adjuvant external-beam radiation therapy in early-stage uterine papillary serous and clear cell carcinoma.
    Kim A; Schreiber D; Rineer J; Choi K; Rotman M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e639-44. PubMed ID: 21507584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus.
    Shou H; Yan K; Song J; Zhao L; Zhang Y; Ni J
    Int J Gynaecol Obstet; 2020 Jan; 148(1):96-101. PubMed ID: 31560127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
    Fader AN; Starks D; Gehrig PA; Secord AA; Frasure HE; O'Malley DM; Tuller ER; Rose PG; Havrilesky LJ; Moore KN; Huh WK; Axtell AE; Kelley JL; Zanotti KM;
    Gynecol Oncol; 2009 Nov; 115(2):244-8. PubMed ID: 19712966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.
    Tortorella L; Langstraat CL; Weaver AL; McGree ME; Bakkum-Gamez JN; Dowdy SC; Cliby WA; Keeney GL; Sherman ME; Weroha SJ; Mariani A; Podratz KC
    Gynecol Oncol; 2018 May; 149(2):291-296. PubMed ID: 29550183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.